Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Core Insights - Evaxion A/S is developing a new preventive vaccine, EVX-B4, against Group A Streptococcus (GAS), which causes hundreds of millions of infections globally each year [1][2] - The AI-Immunology™ platform has been utilized to identify novel vaccine targets for GAS, enhancing the speed and effectiveness of target discovery and preclinical development [2][3] - The addition of EVX-B4 to the R&D pipeline aligns with Evaxion's strategy to increase partnership opportunities and out-licensing assets [4][9] Company Overview - Evaxion is a clinical-stage TechBio company focused on AI-driven vaccine development, with a pipeline that includes five infectious disease candidates and three cancer candidates [4][10] - The company aims to transform patient care by providing innovative immunotherapies for high unmet medical needs in cancer and infectious diseases [10] Industry Context - Group A Streptococcus infections can lead to severe health complications, including rheumatic heart disease and necrotizing fasciitis, with significant mortality rates if untreated [5][6] - The U.S. has seen an increase in invasive GAS disease rates since 2014, with an estimated 20,000 to 27,000 cases and 1,800 to 2,400 deaths annually [6] - Globally, rheumatic heart disease is a major cause of cardiovascular disease, with the World Health Organization estimating 470,000 new cases of acute rheumatic fever and 282,000 new cases of rheumatic heart disease each year [7]